Current combination chemotherapy regimens for metastatic breast cancer

American Journal of Health-System Pharmacy

Volumn 66, Issue SUPPL. 6, 2009, Pages

  Schwartz, Joanna ^a  

^a ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

Author keywords

Antineoplastic agents; Bevacizumab; Breast neoplasms; Capecitabine; Combined therapy; Ixabepilone; Lapatinib; Mechanism of action; Mortality; Neoplasm metastasis; Paclitaxel; Site of action; Toxicity

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTIBIOTIC AGENT; BEVACIZUMAB; CAPECITABINE; CLINDAMYCIN; CORTICOSTEROID; DIPHENHYDRAMINE; DOXYCYCLINE; EPOTHILONE DERIVATIVE; GEMCITABINE; HYDROCORTISONE; IXABEPILONE; LAPATINIB; LOPERAMIDE; MINOCYCLINE; NAVELBINE; PACLITAXEL; RANITIDINE; TAXANE DERIVATIVE; TRASTUZUMAB; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIMETABOLITE; BIOLOGICAL PRODUCT; CYTOTOXIN; DEOXYCYTIDINE; FLUOROURACIL; MONOCLONAL ANTIBODY; QUINAZOLINE DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; BREAST CANCER; BREAST METASTASIS; CANCER SURVIVAL; CELL PROLIFERATION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONFERENCE PAPER; DIARRHEA; DRUG CONTRAINDICATION; DRUG COST; DRUG DOSE REDUCTION; DRUG ERUPTION; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY SKIN; FATIGUE; HAIR; HAND FOOT SYNDROME; HEART DISEASE; HUMAN; INFUSION REACTION; INJECTION SITE REACTION; INTERSTITIAL PNEUMONIA; LIVER TOXICITY; MYALGIA; NAIL DISEASE; NEUTROPENIA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PRURITUS; QT PROLONGATION; QUALITY OF LIFE; SENSORY NEUROPATHY; SEPSIS; SIDE EFFECT; SKIN MANIFESTATION; STOMATITIS; TUMOR CELL; UNSPECIFIED SIDE EFFECT; ANALOGS AND DERIVATIVES; BREAST NEOPLASMS; CHEMICALLY INDUCED; DRUG DELIVERY SYSTEM; DRUG EFFECTS; FEMALE; SIGNAL TRANSDUCTION; SKIN DISEASES;

ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOLOGICAL PRODUCTS; BREAST NEOPLASMS; CYTOTOXINS; DEOXYCYTIDINE; DIARRHEA; DRUG DELIVERY SYSTEMS; EPOTHILONES; FEMALE; FLUOROURACIL; HUMANS; QUINAZOLINES; SIGNAL TRANSDUCTION; SKIN DISEASES;

EID: 73649104457     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp090438     Document Type: Conference Paper

References (24)

1. American Cancer Society. Cancer facts and figures 2009. www.cancer.org/downloads/STT/500809web.pdf (accessed 2009 Jul 13).
2. American Cancer Society. American Cancer Society's Tell-A-Friend program can be a lifesaver. www.cancer.org/docroot/COM/content/div-Northwest/COM-1-1x- American-Cancer-Societys-Tell-A-Friend-Program-Can-Be-a-Lifesaver.asp (accessed 2009 May 1).
3. National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology. Breast cancer, V.1.2009. www.nccn.org/professionals/physician-gls/ PDF/breast.pdf (accessed 2009 May 1).
4. Carrick S, Parker S, Thornton CE et al. Single agent versus combination chemotherapy for metastatic breast cancer. Cochrane Database Syst Rev. 2009; 2:CD003372.
5. Nahta R, Yu D, Hung MC et al. Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer. Nat Clin Pract Oncol. 2006; 3:269-280 (Pubitemid 43731112)
6. Trastuzumab prescribing information. South San Francisco, CA: Genentech, Inc.; 2009.
7. Colozza M, de Azambuja E, Personeni N et al. Achievements in systemic therapies in the pregenomic era in metastatic breast cancer. Oncologist. 2007; 12:253-270 (Pubitemid 46556792)
8. Food and Drug Administration. What's new from the Office of Oncology Drug Products. www.fda.gov/AboutFDA/CentersOffices/CDER/ucm093885.htm (accessed 2009 Jul 21).
9. Halterman PA. Lapatinib and ixabepilone for the treatment of metastatic breast cancer. Pharmacotherapy. 2008; 28:1255-66.
10. Thomas ES, Gomez HL, Li RK et al. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol. 2007; 25:5210-5217
11. Thomas ES. Ixabepilone plus capecitabine for metastatic breast cancer progressing after anthracycline and taxane treatment. J Clin Oncol. 2008; 26:2223. Letter.
12. Ixabepilone prescribing information. New York: Bristol-Meyers Squibb; 2007.
13. Geyer CE, Forster J, Lindquist D et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med. 2006; 355:2733-2743 (Pubitemid 46021510)
14. Cameron D, Casey M, Press M et al. A phase III randomized comparison of lapatinib plus capecitabine versus capecitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res Treat. 2008; 112:533-543
15. Lapatinib prescribing information. Brentford, London: GlaxoSmithKline; 2008.
16. O'Shaughnessy J, Blackwell KL, Burstein H et al. A randomized study of lapatinib alone or in combination with trastuzumab in heavily pretreated HER2+ metastatic breast cancer progressing on trastuzumab therapy. Paper presented at 44th American Society of Clinical Oncology Annual Meeting. Chicago, IL; 2008.
17. Robert C, Soria JC, Spatz A et al. Cutaneous side-effects of kinase inhibitors and blocking antibodies. Lancet Oncol. 2005; 6:491-500. (Pubitemid 40903630)
18. Lacouture ME, Laabs SM, Koehler M et al. Analysis of dermatologic events in patients with cancer treated with lapatinib. Breast Cancer Res Treat. 2009; 114:485-93.
19. Perez EA, Koehler M, Byrne J et al. Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials. Mayo Clin Proc. 2008; 83:679-686 (Pubitemid 351810568)
20. Lynch TJ Jr, Kim ES, Eaby B et al. Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management. Oncologist. 2007; 12:610-621 (Pubitemid 350012125)
21. Gressett SM, Stanford BL, Hardwicke F. Management of hand-foot syndrome induced by capecitabine. J Oncol Pharm Pract. 2006; 12:131-141 (Pubitemid 44696441)
22. Boehnke Michaud L. The optimal therapeutic use of ixabepilone in patients with locally advanced or metastatic breast cancer. J Oncol Pharm Pract. 2009; 15:95-106.
23. Crown JP, Burris HA 3rd, Boyle F et al. Pooled analysis of diarrhea events in patients with cancer treated with lapatinib. Breast Cancer Res Treat. 2008; 112:317-25.
24. Benson AB 3rd, Ajani JA, Catalano RB et al. Recommended guidelines for the treatment of cancer treatment-induced diarrhea. J Clin Oncol. 2004; 22:2918-2926